Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14342664 | 0.85 | CTSL (0.54) | ATMKDM4EPKMALDH1A1 | |
| SCHEMBL14342623 | 0.85 | CTSL (0.54) | ATMKDM4EPKMALDH1A1 | |
| SCHEMBL4075417 | 0.83 | KDM4E (0.45) | ATMEPHX2KDM4EPKMHSD11B1 | |
| SCHEMBL4963939 | 0.81 | HSD11B1 (0.65) | ATMEPHX2HSD11B1MEN1KMT2A | |
| SCHEMBL610249 | 0.81 | HSD11B1 (0.65) | ATMEPHX2HSD11B1MEN1KMT2A | |
| SCHEMBL4077783 | 0.81 | ATM (0.47) | ATMEPHX2KDM4EPKMHSD11B1 | |
| SCHEMBL14342615 | 0.81 | ATM (0.46) | ATMEPHX2KDM4EPKMHSD11B1 | |
| SCHEMBL4518487 | 0.79 | ATM (0.65) | ATMKDM4EPKMKMT2AHTR2A | |
| SCHEMBL4077779 | 0.79 | ATM (0.45) | ATMEPHX2KDM4EPKMHSD11B1 | |
| SCHEMBL1014809 | 0.78 | PKM (0.67) | ATMKDM4EPKMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796793-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20070293477-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2007-12-20 | — | — | US | disclosed |
| EP-1796793-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006029154-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293477-A1 | Novel Compounds | HRH4, TRPV4, TRPC4 | ATM 4424/4885EPHX2 891/4885KDM4E 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.